Sunshine Biopharma Inc.(SBFM)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Sunshine Biopharma Inc. (SBFM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SBFM at 33.1/100 on a 32-signal composite quality model, placing it at rank #2,247 of 2,819 stocks — the bottom half of the AI-ranked universe. SBFM scores in the top quartile across revenue growth (85.8). Areas of concern include revenue scale (8.0) and balance sheet strength (11.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Sunshine Biopharma Inc. reports quarterly revenue of $9.3M, net income of $-1.6M, an operating margin of -17.4%. Top institutional holders of SBFM by reported 13-F value include JANE STREET GROUP, MORGAN STANLEY, UBS Group AG, based on the most recent SEC filings. SBFM trades on the Nasdaq exchange and files with the SEC under CIK 1402328. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SBFM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sunshine Biopharma Inc. directly from SEC EDGAR.